Compare Oklo Inc (OKLO) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Oklo Inc vs ResMed Inc. — how do they compare? Oklo Inc trades at $41.6 (market cap $7.92B), while ResMed Inc. trades at $219.5 (market cap $31.73B). The key difference: ResMed Inc. is far larger — about 4× Oklo Inc's market cap, and ResMed Inc. pays a 1.2% dividend while Oklo Inc pays none. Which is the better fit depends on your goals.
| OKLO | RMD | |
|---|---|---|
Market Cap | $7.92B | $31.73B |
Sector | Technology | Health |
52-Week High | $174.14 | $283.28 |
52-Week Low | $36.84 | $182.82 |
Enterprise Value | $5.46B | $31.08B |
Dividend Yield | — | 1.2% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
OKLO trades at $43.31, up 4.94% in the last 24 hours, with a bullish technical signal from moving averages and neutral oscillators. The stock shows significant losses with a net income margin of -12,625.54% and negative cash flow from operations, but strong financing inflows support growth investments. Recent news highlights progress in small modular reactor projects amid sector volatility, with a 52-week low of $36.61 indicating potential support levels.
Outlook: Wall Street consensus is bullish with a $71.58 price target, driven by AI power demand and nuclear energy tailwinds. Risks include project delays, high cash burn, and lack of profitability. The stock offers high growth potential but requires tolerance for execution risk and extended timelines to commercialization.
ResMed (RMD) trades at $221.05, down 3.2% on the day, with a bearish technical signal and key support at $218. The company reported strong Q4 2026 results, beating EPS estimates at $2.95, and maintains robust profitability with a 26.94% net income margin. Revenue growth remains solid, reaching $5.15B in 2025, though weak 2027 sales guidance has pressured the stock. A dividend of $0.66 is scheduled for payment in September 2026.
Outlook is mixed: strong fundamentals and a consensus price target of $235.70 suggest upside, but bearish technicals and investor lawsuits pose near-term risks. The stock offers value with a P/E of 21.19, yet competitive and regulatory challenges require monitoring for sustained growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Oklo Inc
Oklo Inc. is a company focused on developing and commercializing advanced fission power plants. The company specializes in micro-reactor technology, specifically the Aurora design, which uses advanced fuel to produce reliable, clean, and cost-competitive power. Oklo aims to provide scalable, on-site power solutions to various customers, including remote communities, industrial facilities, and government entities, positioning itself as an innovator in the next generation of nuclear energy.
Read more on OKLO →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
